Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC
Your view on HKMPY
Overview
What the company does, where it operates, and who runs it.
About Hikma Pharmaceuticals PLC
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Said Samih Taleb Darwazah
- Headquarters
- 1 New Burlington Place, London, GB
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Said Samih Taleb Darwazah
- Headquarters
- 1 New Burlington Place, London, GB
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.
The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets.
The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally.
The company was founded in 1978 and is based in London, the United Kingdom.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Hikma Pharmaceuticals PLC, and the rating behind it. HKMPY last traded at $45.06, 11.6× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Hikma Pharmaceuticals PLC. Starting points for Hikma Pharmaceuticals PLC: P/E 11.6, EPS $3.65, beta 0.71 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Hikma Pharmaceuticals PLC. Hikma Pharmaceuticals PLC does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Hikma Pharmaceuticals PLC. Trailing twelve-month EPS for Hikma Pharmaceuticals PLC stands at $3.65. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Hikma Pharmaceuticals PLC. Hikma Pharmaceuticals PLC has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Hikma Pharmaceuticals PLC valued side by side against its closest peers. Hikma Pharmaceuticals PLC is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Hikma Pharmaceuticals PLC, and how their positions are changing. At a $4.97B market value, institutional positions materially move Hikma Pharmaceuticals PLC's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Hikma Pharmaceuticals PLC executives and directors. Shares of Hikma Pharmaceuticals PLC have traded between $39.93 and $58.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Hikma Pharmaceuticals PLC. Hikma Pharmaceuticals PLC is a $4.97B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Hikma Pharmaceuticals PLC. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Hikma Pharmaceuticals PLC. Coverage tracks Hikma Pharmaceuticals PLC within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.